Zydus Lifesciences Limited has successfully wrapped up its share buyback program, demonstrating strong investor confidence and strategic capital management. The pharmaceutical company repurchased 59,70,149 equity shares at INR 1,005.00 per share, utilizing a total of INR 599.99 crore, exclusive of transaction costs.

Overwhelming Response

The buyback initiative received an exceptionally positive response from shareholders, with the offer being oversubscribed by 8.66 times. A total of 45,308 valid bids were received for 5,16,87,188 equity shares, highlighting the strong demand and investor interest in the company's stock.

Buyback Details

Impact on Share Capital

Following the completion of the buyback, Zydus Lifesciences' paid-up share capital will see a reduction:

Key Participant

The Zydus Family Trust emerged as the largest participant in the buyback program, with their tendered shares representing 64.53% of the total shares bought back. This significant participation by the promoter group underscores their confidence in the company's future prospects.

Buyback Mechanism

The share repurchase was conducted through a tender offer route, utilizing the stock exchange mechanism. ICICI Securities Limited served as the manager for the buyback program, overseeing its execution and ensuring compliance with regulatory requirements.

This successful completion of the share buyback program reflects Zydus Lifesciences' commitment to enhancing shareholder value and optimizing its capital structure. The overwhelming response from investors also indicates strong market confidence in the company's financial health and growth prospects.

Zydus Lifesciences Limited , a global innovation-driven healthcare company, has announced a significant addition to its senior management team. The company's Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, has approved the appointment of Nitin D. Parekh as President (Special Projects), effective September 8, 2025, for a two-year term.

Strengthening Management Amid Business Growth

The appointment comes as Zydus Lifesciences aims to reinforce its management team in response to the increasing size, scale, and complexity of its business operations. Parekh, a seasoned professional with over four decades of experience, is set to bring his extensive expertise to this newly created role.

A Stellar Professional Background

Nitin D. Parekh, aged 64, brings an impressive array of qualifications and experience to his new position:

• Educational Background: Chartered Accountant (CA), Chartered Financial Analyst (CFA), and MBA from the Indian Institute of Management, Ahmedabad
• Professional Experience: Over 40 years across finance, strategy, legal, and IT sectors, with a focus on pharmaceuticals and textiles
• Previous Role: Served as Chief Financial Officer at Zydus Lifesciences for more than 16 years

Award-Winning Finance Leader

Parekh's exceptional career is marked by numerous accolades, including:

• Best CFO of Healthcare & Pharma (2025) from Assocham
• Hall of Fame (2024) from CFO Collective
• Excellence in M&A from CII
• Best CFO of India-Large Enterprises from Businessworld (2021)
• Best CFO of Healthcare sector in India from ICAI (2012 and 2017)

Strategic Appointment for Future Growth

The appointment of Nitin D. Parekh as President (Special Projects) is a strategic move by Zydus Lifesciences to leverage his extensive experience in finance, strategy, and general management. His expertise in areas such as M&A, negotiations, deal structuring, and capital structure design is expected to play a crucial role in the company's future endeavors.

Dhaval N. Soni, Company Secretary and Compliance Officer of Zydus Lifesciences Limited, confirmed the appointment in a regulatory filing, emphasizing the company's intent to strengthen its management team in view of its growing business operations and complexity.

As Zydus Lifesciences continues to expand its global footprint in the healthcare sector, the addition of Nitin D. Parekh to its senior management is poised to contribute significantly to the company's strategic initiatives and overall growth trajectory.